Cargando…

Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate

Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require...

Descripción completa

Detalles Bibliográficos
Autores principales: Sisteré-Oró, Marta, Pedersen, Gabriel K., Córdoba, Lorena, López-Serrano, Sergi, Christensen, Dennis, Darji, Ayub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168942/
https://www.ncbi.nlm.nih.gov/pubmed/32312317
http://dx.doi.org/10.1186/s13567-020-00770-4
_version_ 1783523747828858880
author Sisteré-Oró, Marta
Pedersen, Gabriel K.
Córdoba, Lorena
López-Serrano, Sergi
Christensen, Dennis
Darji, Ayub
author_facet Sisteré-Oró, Marta
Pedersen, Gabriel K.
Córdoba, Lorena
López-Serrano, Sergi
Christensen, Dennis
Darji, Ayub
author_sort Sisteré-Oró, Marta
collection PubMed
description Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immunological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that may enhance efficacy of a conserved hemagglutinin (HA)-epitope from IV, the NG-34, to define the most efficient combination of antigen/adjuvant to combat IV infections. Soluble NG-34 was mixed with adjuvants like aluminium hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of mice which were subjected to immunological analyses. CAF01 + NG-34 induced a complete immune response with the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN-γ, IL-2 and TNF-α producing cells. Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-γ, IL-1β, IL-6, IL-10, IL-17 and TNF-α were also the highest in the CAF01 + NG-34 mouse group. This complete induced immune response covering the humoral and the cellular arms of the adaptive immunity promoted by CAF01 + NG-34 group suggests that CAF01 could be a good candidate as an adjuvant to combine with NG-34 for an efficacious vaccine against IV. However, more studies performed in IV hosts as well as studies with a challenge model are further required.
format Online
Article
Text
id pubmed-7168942
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71689422020-04-23 Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate Sisteré-Oró, Marta Pedersen, Gabriel K. Córdoba, Lorena López-Serrano, Sergi Christensen, Dennis Darji, Ayub Vet Res Research Article Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immunological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that may enhance efficacy of a conserved hemagglutinin (HA)-epitope from IV, the NG-34, to define the most efficient combination of antigen/adjuvant to combat IV infections. Soluble NG-34 was mixed with adjuvants like aluminium hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of mice which were subjected to immunological analyses. CAF01 + NG-34 induced a complete immune response with the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN-γ, IL-2 and TNF-α producing cells. Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-γ, IL-1β, IL-6, IL-10, IL-17 and TNF-α were also the highest in the CAF01 + NG-34 mouse group. This complete induced immune response covering the humoral and the cellular arms of the adaptive immunity promoted by CAF01 + NG-34 group suggests that CAF01 could be a good candidate as an adjuvant to combine with NG-34 for an efficacious vaccine against IV. However, more studies performed in IV hosts as well as studies with a challenge model are further required. BioMed Central 2020-04-20 2020 /pmc/articles/PMC7168942/ /pubmed/32312317 http://dx.doi.org/10.1186/s13567-020-00770-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sisteré-Oró, Marta
Pedersen, Gabriel K.
Córdoba, Lorena
López-Serrano, Sergi
Christensen, Dennis
Darji, Ayub
Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title_full Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title_fullStr Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title_full_unstemmed Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title_short Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
title_sort influenza ng-34 t cell conserved epitope adjuvanted with caf01 as a possible influenza vaccine candidate
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168942/
https://www.ncbi.nlm.nih.gov/pubmed/32312317
http://dx.doi.org/10.1186/s13567-020-00770-4
work_keys_str_mv AT sistereoromarta influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate
AT pedersengabrielk influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate
AT cordobalorena influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate
AT lopezserranosergi influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate
AT christensendennis influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate
AT darjiayub influenzang34tcellconservedepitopeadjuvantedwithcaf01asapossibleinfluenzavaccinecandidate